Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.
- DOI
- 10.1158/1078-0432.ccr-17-1574
- Published
- 2017 Nov 1
- Container
- Clinical cancer research : an official journal of the American Association for Cancer Research
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1158/1078-0432.ccr-17-1574,
title = {Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.},
author = {Shi P and Oh YT and Deng L and Zhang G and Qian G and Zhang S and Ren H and Wu G and Legendre B Jr and Anderson E and Ramalingam SS and Owonikoko TK and Chen M and Sun SY},
year = {2017},
journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
doi = {10.1158/1078-0432.ccr-17-1574},
url = {https://doi.org/10.1158/1078-0432.ccr-17-1574}
}RIS
TY - JOUR TI - Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation. AU - Shi P AU - Oh YT AU - Deng L AU - Zhang G AU - Qian G AU - Zhang S AU - Ren H AU - Wu G AU - Legendre B Jr AU - Anderson E AU - Ramalingam SS AU - Owonikoko TK AU - Chen M AU - Sun SY PY - 2017 JO - Clinical cancer research : an official journal of the American Association for Cancer Research DO - 10.1158/1078-0432.ccr-17-1574 UR - https://doi.org/10.1158/1078-0432.ccr-17-1574 ER -
APA
P, S., YT, O., L, D., G, Z., G, Q., S, Z., H, R., G, W., Jr, L. B., E, A., SS, R., TK, O., M, C., & SY, S. (2017). Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-1574
Source records
- pubmed · retrieved 2026-09-27T06:22:26.833Z